Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$887,131.00
Dec 12, 2024
Not-for-profit organization or charity
Critical Technology Transfer Activities to Enable Timely and Cost Effective AAV Biomanufacturing at the BMC- Part II
1023387
The Project will accelerate the rate at which the NRC’s Lipoprotein lipase deficiency (LPLD) AAV-based gene therapy technology is GMP manufactured and readied for testing in the clinic, by formally combining the efforts, experience and expertise of the National Research Council and the Biotherapeutics Manufacturing Centre- Virus Manufacturing Facility (BMC-VMF) at the Ottawa Hospital Research Institute (OHRI).
$169,884.00
Dec 11, 2024
Not-for-profit organization or charity
AI and Machine Learning for Crop Genomics
1025128
Specifically, this project’s primary objective is to develop models that predict gene expression directly from DNA sequences. This collaboration at the intersection of AI and the biology of plant proteins will extract meaningful biological patterns and produce valuable information for future research and application in diverse agricultural fields.
$254,199.00
Dec 9, 2024
For-profit organization
AAV packaging cell line generation.
1024275
The project aims to further develop the D19 clone into a user-friendly cell line for producing AAV vectors, enhancing supply for laboratories working on AAV-based gene therapies. The D19 cell line was generated by NRC from suspension and serum-free media-adapted HEK293SF cells. Using lentiviral vectors, this parental cell line was modified to integrate into its genome a gene expression regulation system induced by the addition of cumate and coumermycin to express AAV Rep proteins (Rep40 and Rep68).
$278,187.00
Dec 6, 2024
Not-for-profit organization or charity
Voices of ManTalk: Building Capacity and Sharing Knowledge about Working with Marginalized Victims of Sexual Abuse
13273119
ManTalk 2.0 is a therapy program for male-identified survivors of sexual abuse.
$75,000.00
Dec 1, 2024
For-profit organization
Feasibility and Integration of AI-Assisted Therapy for Addiction Recovery
1024637
This project explores the feasibility of AI-assisted therapy for addiction recovery for initiating the development of AlchemistOne's go-to-market version.
$15,000.00
Dec 1, 2024
For-profit organization
Develop digital adoption plan
$15,000.00
Nov 20, 2024
For-profit organization
Develop digital adoption plan
$75,000.00
Nov 1, 2024
For-profit organization
MNC Collab - FOCUS2024 - Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye
1024027
As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation of the safety and effectiveness of a gene, encoded in partner mRNA, in correcting an ophthalmological disease when delivered to the eye using Firm's proprietary drug delivery technology platform.
$75,000.00
Nov 1, 2024
For-profit organization
Pre-clinical R and D of a novel non-opioid drug for the treatment of chronic pain
1024974
The company has validated its’ proprietary compounds on this new pain therapy target and the current project will concentrate on the chemical synthesis and biological validation studies to identify and develop back-up compounds as a risk mitigation strategy for the lead compounds currently in development.
$484,000.00
Nov 1, 2024
Academia
ARIADNE: platform for Accelerated and pRecisIon pAndemic Diagnostics and iNfection hEalth
1024053
It integrates NRC's microfluidic technology with novel gene circuit-based molecular sensors, facilitated by machine learning algorithms for biomarker refinement.